Rat Progesterone PharmaGenie ELISA Kit (SBRS0151)

Quantitative progesterone measurement in rat experimental models underpins research in reproductive biology, endocrinology, and pharmacology, and this competitive immunoassay kit from Assay Genie supports those workflows. The platform quantifies progesterone concentrations across cell culture supernatants, plasma, and serum samples harvested from rodent studies, providing researchers with a practical tool for hormone-level monitoring and characterisation of steroidogenesis pathways.

Each kit provides reagents sufficient for 96 individual assay determinations and is validated for use with the sample matrices commonly generated in rat protocols. The competitive ELISA format is well suited to small steroid analytes like progesterone, where the target analyte competes with a labelled conjugate for antibody binding sites rather than being captured in a sandwich-style configuration. This approach delivers a colorimetric end-point that can be read on a standard microplate reader, integrating easily into existing laboratory workflows.

Typical applications include monitoring circulating progesterone across the rat estrous cycle, assessing luteal function in pseudopregnancy or pregnancy models, screening compounds for endocrine activity in pharmacology studies, and characterising hormone secretion from cultured granulosa or Leydig cells. Researchers studying reproductive aging, ovariectomy effects, or hypothalamic-pituitary-gonadal axis interventions also rely on quantitative progesterone readouts to validate experimental outcomes.

Assay Genie equips the kit with all buffers, standards, and detection reagents needed to run the full plate, along with a protocol outlining sample preparation, dilution guidance, and incubation steps. Samples should be aliquoted prior to assay to limit freeze-thaw cycles. The competitive design complements sandwich-format immunoassays when measuring low-molecular-weight hormones, and the 96-assay configuration suits both small pilot studies and larger screening campaigns.